Last reviewed · How we verify
UMEC DPI
UMEC (umeclidinium) is a long-acting muscarinic antagonist that blocks M3 receptors in airway smooth muscle to produce bronchodilation.
UMEC (umeclidinium) is a long-acting muscarinic antagonist that blocks M3 receptors in airway smooth muscle to produce bronchodilation. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.
At a glance
| Generic name | UMEC DPI |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Umeclidinium binds to muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. This results in sustained airway relaxation and improved airflow. It is formulated as a dry powder inhaler (DPI) for once-daily maintenance therapy in chronic obstructive pulmonary disease (COPD).
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance therapy
Common side effects
- Tremor
- Headache
- Palpitations
- Tachycardia
- Urinary retention
Key clinical trials
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
- A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma (PHASE3)
- Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma (PHASE2)
- INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design (PHASE4)
- Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness
- A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
- Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- UMEC DPI CI brief — competitive landscape report
- UMEC DPI updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI